We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 0.25% | 40.70 | 41.00 | 41.25 | 41.80 | 40.00 | 40.40 | 612,822 | 16:35:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -21.13 | 123.29M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/2/2024 10:17 | Plenty of polite low-lives in this world. | broomrigg | |
18/2/2024 08:15 | Efficacy improved after the first dose and men achieved an erection within 10 minutes in 60% of applications. There were 3,792 intercourse attempts and two-thirds (63%) of men achieved or exceeded the Minimal Clinically Important Difference (MCID), which is the benchmark for a meaningful response. The speed of onset was significantly faster than oral PDE5i medicines, which typically start to work within 30-60 minutes. At 12 weeks, men using Eroxon showed significant improvement from baseline across all measures, with the response increasing in line with the severity of their ED. Four in five (80%) of those with the most severe ED met, and in some cases exceeded, MCID. In men with moderate ED, 59% met or, again in some cases, exceeded MCID and in those with mild ED it was 61%. Reported side effects were minimal and significantly lower than those typically associated with PDE5i medicines. You do not need to be a medic to understand these results - surely. dyor etc. Perhaps the wisest review on Amazon to date that made me smile :) Reviewed in the United Kingdom on 11 February 2024 Verified Purchase Did not return me to the first flush of youth. But just on first use did enough to ensure entry to the lock. Previous reviewers reported even better on results with subsequent use. Some say did not work. Could that be partly down to lack of enthusiasm from the lock. | takeiteasy | |
18/2/2024 07:55 | It's time people started to use the filter button here instead of keeping the trolls alive but answering their diatribe. | 2 solaris | |
17/2/2024 22:38 | Comments about the UAT or user acceptance testing stage are done before go live - we are live MDI so any comments about the extent to which you think testing was or was not sufficient is entirely irrelevant. We now rely on feedback from live use following regulatory approvals. You know this of course so more silly time wasting. | takeiteasy | |
17/2/2024 20:28 | I have been in this share for a good number of years and followed this board. The last few weeks contributions to the board have been the best yet. Really constructive, informative and genuinely helpful - thank you! As Petroc has mentioned we have endured years and years of rubbish, make your own minds up on this one!In terms of my contribution, my experience of FUM, particularly over the last few years is that they have hit every target mentioned in their previous RNSs. Look back and see for yourself. Also, consider their people hires. They recruited an ex Boots guy and guess what, Eroxon ended up in Boots. They have recently recruited a commercial trading big hitter so suspect there are many deals in the pipeline. Remember the biggest opportunity success brings is the opportunity for more success! | k8 rhm | |
17/2/2024 19:19 | This MDI is funny, he thinks he knows more than Haleon or the others that have partnered with FUM. We can all celebrate at the 50-60p club next week | phatstyle321 | |
17/2/2024 19:13 | I just saw Eroxon advertised on ITV4! People will cotton onto this sooner than later. | 2 solaris | |
17/2/2024 19:05 | Lower class medical devices are not tested to strict efficacy criteria Momentum grows to subject medical devices to medicines gold standard the placebo treatment Eroxon Is Not a Medication? No. Because it lacks an active ingredient, the FDA granted MED3000 a CE mark at the end of the trial, which classifies it as a medical device not a medication. Thats important because in European markets, medical devices dont have to show any sort of improvement in symptoms; they just have to meet specific safety standards. In other words, the CE mark proves only that Eroxon is safe, not that it works. | mdi | |
17/2/2024 18:21 | MDI placebo argument is so totally flawed from every possible angle - it has been comprehensively tested and approved within strict criteria from US and UK authorities. It is the one place we stand on the strongest possible ground - so this person needs to find another item to pick a battle over :) | takeiteasy | |
17/2/2024 18:17 | Full panic mode at the weekend - surely not ...sadly for him I suspect it might even create the one outcome he does not want ... | takeiteasy | |
17/2/2024 18:12 | Looks like we're in for a big rise this coming week - whenever MDI/LBO etc posts his rubbish this frantically it usually presages a spike in the SP! | petroc | |
17/2/2024 18:05 | So a mate rubs deep heat on their calf and gets a spontaneous erection and phones their doctor all anxious who replies - sorry, I forgot to tell you deep heat is a placebo and much safer to use Eroxon instead :) I actually think MDI is goading everyone with this rubbish to go long sadly to break out of the price range and so he then is silenced - dyor and no advice etc... | takeiteasy | |
17/2/2024 17:49 | But Eroxon wasn’t studied against any placebo gel? Even the Eroxon website itself contradicts the ‘qualified urologist’? And the ‘qualified urologist’ has another video explaining how important it is to have placebo blinded studies in ED? Eroxon, was the “placebo&rdquo The company that makes MED3000 (Eroxon) also made a different compound called MED2005, a nitroglycerine-conta The company then decided to market the placebo compound itself as Eroxon, which does not contain nitroglycerine or any compound that is expected to have a pharmacologic effect | mdi | |
17/2/2024 17:34 | hxxps://youtu.be/qCm This video gives a testimonial from a qualified urologist over 2.5 million views this puts most of the naysayers at bay | phatstyle321 | |
17/2/2024 16:11 | Yet Eroxon has never been clinically proven to have any effect beyond a similar placebo gel in any blind study in men with ‘diabetes or CV disease’. See all the inclusion and exclusion criteria for the Eroxon studies and ‘given that the most affected patients were excluded’. Even men who had experienced significant side effects with PDE5I drugs were excluded. So again no evidence Eroxon works any better then a placebo gel in that group either as they were also excluded. ‘Any history of unresponsiveness to PDE-5 treatment or significant side-effects’ ‘Exclusion criteria include: any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic’ ‘I know that many men are willing to do almost anything to treat erectile dysfunction. I am also supportive of the placebo response when it is used ethically. However, I have a hard time recommending paying $100 for a compound that was designed and tested as a placebo, even if 37% of men will find some benefit from it’ ˜the positive effect of the placebo in this clinical trial is all the less surprising given that the most affected patients were excluded, in particular those for whom the erectile problems could be explained by another pathology’ ‘In the real world, there are no exclusion criteria’ ‘policy to reduce the amount of money the NHS spends on prescriptions for treating minor conditions that usually get better on their own’ ‘GP said my problem was stress related rather than anything physical, and would resolve itself’ | mdi | |
17/2/2024 06:18 | We both can agree the ED market has enormous potential and well done for noting the high numbers of presciptions that back up the numbers I posted earlier. You seem rather confused over how the process will work - quite simpy, we need both routes to market - OTC and GP prescriptions. Either If you can self-diagnose that your ED issue is temporary and not part of a long term medical condition then buy OTC and you pay for Eroxon yourself Or If you are concerned that you have a long term health issue like diabetes or CV disease then go to you GP who will prescribe Eroxon where the blue pill is not a viable option and you either pay the standard amount for the prescription or you have a medical exemption certificate if specific circumstances apply We get paid in both cases....which is why you need to get the messaging via NHS route and via the street via ads on mainstream TV and via the press. NHS was already getting the message back in April 2023 that Eroxon is the way forward for ED - very encouraging: Dr Hood says she will recommend Eroxon to her patients – if they haven’t tried it already before seeing her...The great thing about it is that it is so simple and quick, and there is nothing to lose by trying it.” | takeiteasy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions